Page 1 of 58 Diabetes DB16-0887 Mafa enables Pdx1 to effectively convert pancreatic islet progenitors and committed islet ααα-cells into βββ-cells in vivo Taka-aki Matsuoka1,***, Satoshi Kawashima1, Takeshi Miyatsuka1,2, Shugo Sasaki1, Naoki Shimo1, Naoto Katakami1, Dan Kawamori1, Satomi Takebe1, Pedro L. Herrera3, Hideaki Kaneto4, Roland Stein5, Iichiro Shimomura1 1 Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan 2 Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, Tokyo, Japan 3 Department of Genetic Medicine and Development, University of Geneva Faculty of Medicine, CH-1211 Geneva 4, Switzerland 4 Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Okayama, Japan 5 Department of Molecular Physiology & Biophysics, Vanderbilt University Medical School, 723 Light Hall, Nashville, TN 37232, U.S.A. *Corresponding author. Address: 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan Tel: 81-6-6879-3743 Fax: 81-6-6879-3739 e-mail:
[email protected] Key words: islet α cells, β cells, transdifferentiation, Mafa, Pdx1, diabetes - 1 - Diabetes Publish Ahead of Print, published online February 21, 2017 Diabetes Page 2 of 58 Abstract Among the therapeutic avenues being explored for replacement of the functional islet β-cell mass lost in Type 1 diabetes (T1D), reprogramming of adult cell types into new β-cells has been actively pursued. Notably, mouse islet α-cells will transdifferentiate into β-cells under conditions of near β-cell loss, a condition similar to T1D. Moreover, human islet α-cells also appear to poised for reprogramming into insulin+ cells.